{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-001396","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.750533+00:00","generated_at":"2026-05-31T06:12:20.851412+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lexaria appoints Richard Christopher as CEO; Bunka transitions to Chairman","bullets":["Richard Christopher, 54, appointed CEO effective Aug 31, 2024; he also serves as interim CFO until new CFO is hired.","Christopher receives 200,000 stock options at $3.92, base salary with 5% annual raises in 2025-26, and 50% of salary bonus target.","Outgoing CEO Bunka's letter: $8.5M raised YTD 2024, market cap ~$60M, Phase 1b hypertension study expected H1 2025.","GLP-1 R&D shows positive data; DehydraTECH-CBD outperforms in weight loss and blood sugar control in animal studies.","Bunka remains Chairman and Executive Strategic Advisor; cites need for pharma operational expertise for execution phase."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-001396","json":"https://secwatch.observer/filing/0001640334-24-001396.json","markdown":"https://secwatch.observer/filing/0001640334-24-001396.md","text":"https://secwatch.observer/filing/0001640334-24-001396.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:12:20.851412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bfe18faf0","claim":"Richard Christopher was appointed as Chief Executive Officer at Lexaria Bioscience Corp..","evidence_excerpt":"appointed Richard Christopher, age 54, to the position of Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"17f47d9cf5","claim":"Christopher Bunka changed role as Chairman of the Board at Lexaria Bioscience Corp..","evidence_excerpt":"replacing Christopher Bunka who will remain as the Company’s Chairman of the Board and as a strategic advisor","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424001396/0001640334-24-001396-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}